Matt Hancock gives verdict on botched Covid 'test and trace' operation

Former health secretary Matt Hancock is grilled at the Covid-19 Inquiry about setting up a privatised "test and trace" service which failed to prevent repeated lockdowns
Matt Hancock has defended Britain's botched pandemic 'test and trace' operation at the Covid-19 Inquiry which failed to prevent repeated lockdowns.
The former Health Secretary outsourced the nation's vital contact tracing rather than beefing up existing NHS and local public health laboratories and its failure contributed to the need for further lockdown measures. The disgraced ex-minister blamed health leaders for being unable to scale up testing laboratories, insisting 'Public Health England didn't have the operational capacity to scale [up]'
‌
The Tories' privatised 'NHS Test and Trace' operation was set up in May 2020 costing £37 billion and led by Mr Hancock's friend, Tory Peer Baroness Dido Harding.
‌
Outsourcing firms like Serco were paid millions to call people and advise them to self-isolate but used agency call centre staff paid the minimum wage who were largely not medically trained.
The former I'm a Celebrity Get Me Out of Here contestant said: 'The critical thing is that we absolutely must, as a nation, be ready to expand and radically expand testing capacity. Once the test is developed, I had to do that.
'And there are critics who said that it was done in the wrong way. What matters is that it's done and it is planned for next time to be ready to be done.'
PM Boris Johnson promised a " world beating" system but the Public Accounts Committee later found NHS Test and Trace failed in its main objective of breaking chains of COVID-19 transmission. A BBC investigation at the time showed only half of close contacts were being reached in some areas.
‌
Mr Hancock said Public Health England (PHE) 'proved entirely incapable of expanding that testing capacity', adding: 'It was a cottage industry and we needed industrial scale capacity'.
The inquiry heard how Mr Hancock set up a contract tracing system 'from scratch' rather than providing the funding to upgrade local authority labs and facilities run by PHE.
‌
The barrister questioning Mr Hancock on behalf of the inquiry asked whether he was aware that local contact tracing systems already existed.
Sophie Cartright KC said: 'Did you appreciate that, that the directors of public health within local authority is discharged and performed the role of contact tracing? There was this resource in every local authority across the United Kingdom that had the resources.'
‌
Mr Hancock responded: 'Of course I appreciated that. There was one person in each of the upper tier local authorities and therefore, around 100 people, brilliant people, I engaged with a huge number of them throughout the pandemic. But the idea that they alone could have solved this problem was, unfortunately, the wrong attitude.'
Mr Hancock resigned as health secretary in 2021 after admitting breaching social distancing guidance after photos showed him in a romantic embrace with colleague Gina Coladangelo.
Lack of NHS testing capacity meant testing everyone who had Covid symptoms had to be abandoned early in the pandemic once 'community transmission' was established in the UK.
‌
Mr Hancock told the inquiry: 'The doctrine that we had going into the pandemic, that was shared by most of the Western world and the World Health Organisation, was wrong.
'The advice I received from Public Health England was that we should not need or try to test at scale or contact trace at scale as soon as there was community based transmission. There was no point in testing and contact tracing any further outside of hospitals because, effectively, everybody was going to get infected.
'That was the wrong attitude and it is absolutely critical that next time there's a pandemic… we are ready to take the actions to stop it spreading and protect the most vulnerable first.'
He concluded: 'The single most important thing is to conclude that the industrial scale, expansion of testing is necessary and we need to be ready to do it.'

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

The Independent

2 hours ago

• The Independent

Weight loss pill shows promise in new trial

A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.

South Wales Guardian

3 hours ago

• South Wales Guardian

Weight loss pill shows promise in new trial

An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.

Leader Live

3 hours ago

• Leader Live

Weight loss pill shows promise in new trial

An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.